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Unexpected tolerance of alpha-cleavage of the prion protein to
sequence variations
Abstract
The cellular form of the prion protein, PrP(C), undergoes extensive proteolysis at the alpha site (109K
[see text]H110). Expression of non-cleavable PrP(C) mutants in transgenic mice correlates with
neurotoxicity, suggesting that alpha-cleavage is important for PrP(C) physiology. To gain insights into
the mechanisms of alpha-cleavage, we generated a library of PrP(C) mutants with mutations in the
region neighbouring the alpha-cleavage site. The prevalence of C1, the carboxy adduct of
alpha-cleavage, was determined for each mutant. In cell lines of disparate origin, C1 prevalence was
unaffected by variations in charge and hydrophobicity of the region neighbouring the alpha-cleavage
site, and by substitutions of the residues in the palindrome that flanks this site. Instead, alpha-cleavage
was size-dependently impaired by deletions within the domain 106-119. Almost no cleavage was
observed upon full deletion of this domain. These results suggest that alpha-cleavage is executed by an
alpha-PrPase whose activity, despite surprisingly limited sequence specificity, is dependent on the size
of the central region of PrP(C).
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Introduction
The prion protein is necessary for the development of prion
diseases, also termed transmissible spongiform encephalopathies
(TSEs) [1,2]. The most established molecular model for these
diseases proposes that the cellular form of the prion protein (PrPC)
is refolded into b-sheet-rich aggregates (PrPSc), which constitute
the infectious agent termed prion [3,4]. While the concept of a
nucleic-acid-free infectious agent spreading through protein
aggregation is supported by a large body of evidence, the
mechanisms by which PrPSc aggregates and induces neurotoxicity
are poorly understood [4,5].
Studies on proteolytic processing of PrPC and PrPSc have shown
that PrPC is mainly cleaved in a region termed the a-cleavage site
[6]. In human, bovine, and ovine PrPC, the cleavage has been
reported to occur at the conserved residues 109KQH1110 [7,8,9]
(the residue numbering of murine PrPC is used in this report) in the
unstructured portion of PrPC [10]. The resultant products are the
globular C-proximal and the flexible N-proximal domains (C1 and
N1, respectively) [7]. In contrast, the disease-associated PrPSc
conformer undergoes a process named b-cleavage [6], which
generates a larger C-proximal product designated C2 [7,11]. One
likely explanation for this differential processing is that the a-
cleavage site may be buried within the aggregates of PrPSc [7,11]
and may therefore be protected from proteolysis.
The subcellular site of a-cleavage is controversially discussed.
On the one hand, cleavage is inhibited by ammonium chloride,
suggesting that it occurs in an acidic endocytic compartment [12].
On the other hand, C1 accumulates intracellularly in human SH-
SY5Y cells expressing secreted anchorless PrPC, suggesting that
cleavage occurs in a late compartment of the secretory pathway
[13].
Certain PrPC deletion mutants, such those termed DF
(PrPD23–134) and DE (PrPD23–121) [14], resemble the C1 cleavage
product [7,14] and do not support prion replication [5,15].
Therefore, enhancement of a-cleavage in vivo may diminish the
availability of full-length PrPC for conversion into PrPSc. If this
conjecture proves correct, it will be important to identify the
proteases responsible for cleavage of PrPC, here termed a-PrPases,
and any hypothetical factors that may control their activity.
Moreover, certain PrPC variants bearing deletions close to
the a-cleavage site induce toxicity when transgenically ex-
pressed in mice. Toxicity can be rescued in a dose-dependent
manner by coexpression of normal PrPC [14,15,16,17]. This
raises the question whether the toxicity of these PrPC mutants
may be related to abnormalities in the proteolytic processing of
PrPC.
But which structural determinants of PrPC control the
interaction with the putative a-PrPase? When expressed in
transgenic mice, PrPC mutants bearing large deletions of the a-
cleavage site, such as PrPD94–134, had a complete cleavage
inhibition and were highly toxic in Prnp2/2 mice [14,16], whereas
the downstream deletion PrPD114–121 exhibited some cleavage and
showed only mild toxicity [14]. This in vivo data on proteolytic
processing of PrPD94–134 replicate the observation that PrPD95–132
is not cleaved when expressed in Hpl cells [18].
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Other studies on PrPC processing in cultured cells suggest that the
alanine and glycine residues in the PrPC palindromic region
localized in the downstream flank of the a-cleavage site may be
important for a-cleavage [19]. It was reported that in transfected
N2a cells, PrPC bearing two point mutations that transformed the
palindromic domain 112–119 into an alanine chain had no
remarkable impairment in a-cleavage [19]. Conversely, the cleavage
product C1 was not, or very weakly, detectable in constructs where
this palindrome was converted into a glycine chain, or where region
105–125 was deleted [19]. Other studies also suggested that a-
cleavage is not affected by the removal of the octapeptide region
[15,18,20] or by the insertion of supernumerary octapeptide repeats
[20]. a-cleavage of PrPC mutants was also assessed in cells
expressing ovine PrP (ovPrP) with GFP inserted into the N-proximal
region [21]. In this system, the point mutations ovPrPK113R,
ovPrPK113D, ovPrPK113A and ovPrPKHV113–115AAA did not appear to
affect cleavage, with the respective mutant proteins processed
similarly to the fusion protein of wild-type ovPrPC with GFP.
Here we attempted to test certain predictions regarding the
sequence requirements to PrPC for a-cleavage. We confirmed that
the murine PrPC domain 106–119 is indeed important for PrPC
cleavage. In addition, we found that PrPC cleavage was
independent of the precise sequence at the cleavage site, and
was largely independent of the charges and hydrophobicity in the
vicinity of a-cleavage site. Instead, the efficacy of a-cleavage was
linearly dependent on the size of deletions between residues 106–
119. Likewise, substitutions of alanines to glycine residues in the
PrPC palindromic region 112–119 had no influence on the degree
of C1 generation. Finally, we did not detect any C1 generation in
lysates of murine Prnp2/2 cells and brains expressing anchorless
secreted PrPC (secPrPC) indicating that cleavage is membrane
anchor-dependent.
Results
Characterization of a-Cleavage of PrPC in Various Cell
Lines
We assessed the glycosylation and a-cleavage of PrPC in cell
lines transfected with constructs encoding PrPC and the mutant DF
[15], which almost completely lacks the N-proximal region and
displays an electrophoretic mobility similar to that of C1 [14,15]
(Fig. 1A–B). The cell lines used were the murine neuroblastoma
cell line N2a-PK1 [22], the murine fibroblast cell line NIH3T3
[23], and the Npl and Hpl3–4 cell lines derived from Prnp-ablated
mice [24,25].
We found that the extent of glycosylation of both PrPC and DF
was quantitatively and qualitatively similar in each of the above
cell lines (Fig. 1A), and essentially corresponded to that of brain
tissue (data not shown). Upon deglycosylation with PNGase, a
sharp C1 band with electrophoretic mobility similar to that of DF
(ca. 15 kDa) was detectable in all cell lines (Fig. 1B). The N-
proximal fragment of a-cleavage was subsequently assessed in
N2a-PK1 cells and in PrPC-transfected Hpl cells. PrPC was
immunoprecipitated from culture media with antibody POM2 and
detected with antibody POM11. Both POM2 and POM11 react
with the octapeptide repeat region of N-proximal PrPC tail [26],
and evidenced the N1 product of a-cleavage (ca. 12KDa; Fig. 1C).
The size of the N-proximal fragment observed here is in
agreement with previous reports in murine TSM1 neurons and in
human HEK293 cells [27], and with chicken PrP in murine N2a
cells [28]. Instead, we did not confirm a report that the dominant
N-terminal band in N2a and GT1 cells has an apparent molecular
weight of 7.6 KDa [6]. The C1 fragment was also detected after
PNGase treatment of total cell lysate of the same cultures (Fig. 1D).
The observation of these two well-defined cleavage fragments, C1
and N1, supports the conjecture that a-cleavage is a controlled
proteolytic process rather than mere exoproteolytic digestion of
the unstructured region by nonspecific proteases.
To assess whether PrPC is universally cleaved in other cell
systems, PrPC and the mutant C39 were transfected into human
HeLa cells [29] (Fig. 1E) and into murine primary embryonic
fibroblasts (MEFs) derived from Prnp2/2 mice (Fig. 1F). C39 lacks
the palindromic region that flanks the a-cleavage site of PrPC
(Fig. 2A), and a deletion within the same region was reported to
impair C1 generation in transgenic mice [14]. In both HeLa and
MEFs the murine PrPC molecule was efficiently cleaved (Fig. 1E–
F), whereas a-cleavage of the mutant C39 was impaired in both
cell lines. We conclude that the structural features that control a-
cleavage of PrPC are common to many cell types of diverse
histogenetic origin, including established murine cell lines, human
cell lines, and murine primary cells.
Impact of Residues Neighbouring the a-Cleavage Site
onto PrPC Processing
The a-cleavage site of PrPC is located between a charge cluster
(CC) and a hydrophobic core (HC), and is flanked N-proximally
by positively charged residues and C-proximally by a palindrome
sequence (Fig. 2A). We first investigated whether the positive
charges at the a-cleavage site contribute to defining the proteolytic
site. For this purpose we designed a series of PrPC mutants with
substitutions of the basic amino acids. In the BOM6 construct we
mutated to neutral alanine residues the two charged amino acids
of the a-cleavage site, whereas in BOM3 we mutated the positive
charges into anionic aspartate residues (Fig. 2A). Because DF and
C1 were previously found to display similar electrophoretic
mobility, DF was used as a molecular size marker for identifying
C1 [14,15].
Cell lysates of lines transfected with PrPC and its mutants were
collected, and PrPC glycosylation and processing were assessed
before and after treatment with PNGase. BOM6, BOM3, and the
deletion mutant DF all underwent glycosylation similarly to PrPC
in both cell lines. Therefore, charge inversion or large deletions in
the flexible N-proximal domain of PrPC did not exert any
appreciable impact onto PrPC glycosylation (Fig. 2B). This
observation is in agreement with reports suggesting that large
alterations in the region of the CC and HC have no measurable
impact in the distribution of the mutants between various cellular
microdomains [14,30].
The N1 fragment is released into the medium, whereas C1 retains
its GPI anchor and its membrane localization. Furthermore, N1
encompasses the unstructured domain of PrP [10] and is unstable.
Because of these circumstances, we reasoned that the degree of
cleavage of the various PrPC mutants would be more reliably
assessed by measuring C1 rather than N1. Therefore, we
quantitated the C1 band and compared it to the integrals of the
band corresponding to uncleaved PrPC (Fig. 2B). In both Hpl and
Npl cells the degree of a-cleavage of BOM6 and BOM3 was
comparable to, or ,25% lower than, that of wild-type PrPC
(Fig. 2B). Hence removal, or even inversion, of the positive charges
at the a-cleavage site did not result in a remarkable inhibition of a-
cleavage. The values for cleavage inhibition of the mutants varied ,
7% between Hpl and Npl cells (Fig. 2B), indicating that the pattern
of proteolytic processing of PrPC in these two cell lines was
qualitatively and quantitatively similar. For this reason we focused
on the Hpl cell line for most of the studies described in the following.
To further test the possibility that a-cleavage is independent of
the charges and sequence of the cleavage site, we designed the
BOM8 mutant in which all five basic histidine and lysine residues
Prion Protein
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neighbouring the a-cleavage site were mutagenized into un-
charged alanines (Fig. 2A). We also asked whether swapping the
position of the a-cleavage site would alter the proteolytic
processing of PrPC. For this the mutant BOM7 was elaborated,
whose a-cleavage site was shifted downstream by two amino acids
(Fig. 2A). We found that the cleavage efficiency of BOM6, BOM8
and BOM7 was between 95 and 100% of the cleavage of wild-type
PrPC. Hence, as with the previously assessed constructs, BOM8
and BOM7 generated C1 with a similar efficiency to that of wild-
type PrPC (Fig. 2C).
Having established that the above modifications had little
impact onto the a-cleavage, we assessed the impact of stronger
alterations of the CC region. For this purpose we analyzed BOM8
together with two constructs bearing charge inversions. FBOM3
had all six cationic residues of the CC mutated into anionic
glutamate residues, resulting in complete inversion of all charges
(Fig. 2A). In FBOM1 the positive charges of four lysines were
inverted into anionic glutamate residues, but these acidic residues
were interspersed with two cationic histidines (Fig. 2A). Constructs
C39 and C40 (which carries a large deletion of the region 100–
Figure 1. Proteolysis of PrPC in various biological models. A–B: Western blots of lysates of various cell lines (N2a-PK1, Npl, NIH3T3, Hpl) non-
treated (A) or treated (B) with PNGase. Cells were transfected with a plasmid encoding PrPC or PrPD32–134; (lanes labeled PrPC and DF, respectively).
Detection was performed with antibody POM1 which recognizes the globular domain of PrP. C–D: Western blot of cell culture media (C) or cell
lysates (D) from N2a-PK1 cells and PrPC-transfected or parental Hpl cells (lanes labelled accordingly). Media (C) were immunoprecipitated
with antibody POM2 and detected with POM11, which both recognize the N-proximal region of PrPC, whereas cell lysates (D) were treated with
PNGase and detected with POM1. E: Western blot of PNGase-treated lysates of human HeLa cells transfected with murine PrPC or with construct C39
(PrPD111–120). Detection was performed with antibody POM19 which recognizes the C-proximal domain of murine, but not human, PrPC. F: Western
blot of PNGase-treated cell lysates of mouse primary mouse embryonic fibroblasts (MEFs) from Prnp2/2 mice. MEFs were transfected with constructs
encoding murine PrPC or C39 (PrPD111–120). Arrows point to the full length PrP (FL) and to the C1 fragment.
doi:10.1371/journal.pone.0009107.g001
Prion Protein
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Figure 2. Proteolysis of PrPC variants with mutations in the palindrome and in the positive charges neighbouring the a-cleavage
site. A: Amino acid sequence alignment of the PrPC constructs used. Numbers represent amino-acid residues in murine PrPC sequence. The
positive residues, the charged cluster, hydrophobic core and palindrome are indicated. Arrow: a-cleavage site. Grey: non-mutated residues. Green:
deletions or mutations into non-charged residues. Blue: mutations into negatively charged residues. Red: mutations into positively charged
residues B: Western blots of cell lysates of Hpl and Npl cells transfected with the various mutants. Samples in the lower blot were deglycosylated
with PNGase. C–D: Western blot of PNGase-treated Hpl cells transfected with the various PrPC mutants. All lanes in (D) belong to the same blot.
Detection was done with POM1. E: Western blot of PNGase treated cell lysates of HeLa cells transfected with various PrPC mutants. Detection was
done with POM19. F: Quantification of the percentage of a-cleavage of the various PrPC mutants, based on densitometry of western blots from
which (D) is representative. Quantifications were calculated in the linear range of the densitometric signal of independent experiments. Values refer
to the amount of C1 generation comparing to total abundance of PrPC, and are normalized to cleavage of wild-type PrPC, which was assessed in
the same blot. Error bars represent standard errors of the mean (SEM). Arrows point to the full length PrP (FL) and to the C1 fragment, which can
also correspond to DF.
doi:10.1371/journal.pone.0009107.g002
Prion Protein
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129) were analyzed in parallel and used as ‘‘molecular milestones’’
for assessing moderate and extensive cleavage inhibition, respec-
tively. Quantitation of the C1 fragment generated in these
constructs and in wild-type PrPC confirmed that removal of the
five positive charges around the a-cleavage site and in the
neighbouring region did not affect the proteolytic processing of
PrPC (Fig. 2D,F). Even extremely drastic modifications, such as the
polarity inversion of four or even six positive charges (FBOM1 and
FBOM3), resulted in only about 38% a-cleavage impairment
(Fig. 2D,F). On the basis of these results it is unavoidable to
conclude that the charges surrounding the a-cleavage site are
largely irrelevant for the proteolysis of PrPC, with neutralization
and even complete charge reversal of the CC region resulting in a
surprisingly slight impairment of a-cleavage.
Role of the PrPC Palindromic Region (111–120) in a-
Cleavage
Next, we studied the residues located carboxy proximally to the
cleavage site. This region contains a palindrome which is
immediately adjacent to the N-terminal boundary of the HC
(Fig. 2A). A previous study reported that substitution of all
palindromic glycines with alanines, as in construct BOM9,
abrogated C1 generation in N2a cells [19]. We therefore assessed
the cleavability of BOM9 and of BOM11, which bears only three
palindromic alanine substitutions, in Prnp2/2 Hpl cells [25]
(Fig. 2A). To our surprise, quantification of C1 revealed that both
constructs were processed by a-cleavage similarly to wild-type
PrPC (Fig. 2D,F). In order to evaluate the robustness of these
results, the palindromic mutants BOM9 and BOM11, the
palindromic-deletion construct C39, and the charge-neutralized
BOM8 were transfected into HeLa cells. Fragments were analyzed
with antibody POM19 which recognizes the globular domain of
murine, but not of human, PrPC [26]. The proteolytic processing
of these mutants was indistinguishable in both HeLa (Fig. 2E) and
Hpl cells (Fig. 2D,F) and was essentially identical to that of wild-
type PrPC (Fig. 2E). In contrast, C39 displayed partial a-cleavage
inhibition in both Hpl and HeLa cells, which is in agreement with
the finding that a mutant bearing a deletion of the region 114–121
is inefficiently cleaved in the brain of transgenic mice [14]. We
conclude that, in contrast to published claims [19], the substitution
of the palindrome with a total or partial polyglycine chain does not
have a measurable impact on a-cleavage of PrPC.
The impact of Hydrophobicity onto a-Cleavage
Another striking feature that might modulate a-cleavage of
PrPC is the strong hydrophobicity of the residues neighbouring the
cleavage site. Since the HC may be associated to the cell
membrane [31], we reasoned that a-cleavage may be affected by
the distance between the cleavage site and the cell membrane. In
this scenario, reduction of the hydrophobicity of the HC may
modify its interaction with the cell membrane and thereby
decrease the rate of a-cleavage.
To test the latter hypothesis, we designed three PrPC constructs
in which we substituted hydrophobic residues with non-ionic
hydrophilic analogues of roughly similar molecular size. Accord-
ingly, we substituted alanine with glycine residues, whereas
leucines and valines were replaced with glutamines (Fig. 3A).
The maximal deviation in primary sequence between each pair of
constructs was four residues. Construct BOM26 displayed only a
slight reduction of hydrophobicity and therefore was expected to
be cleaved almost as efficiently as wild-type PrPC, whereas
BOM27 had a stronger reduction of hydrophobicity (Fig. 3A–B).
Finally, BOM25 bears almost no positive hydrophobic integral
and was designed to stringently test whether hydrophobicity would
play any role in a-cleavage (Fig. 3A–B). Again, constructs C39 and
C40 were used in control experiments and served as molecular
milestones of moderate and extensive inhibition of cleavage,
respectively.
Quantification of C1 generation in constructs BOM26,
BOM27, and BOM25 showed that none of these mutations
impaired the proteolysis of PrPC (Fig. 3D–E). We even observed
slightly increased proteolysis of PrPC, but this increase was similar
for all three mutants and was therefore independent of the
hydrophobicity. Thus, the hydrophobicity of the region neigh-
bouring the a-cleavage site appears to play no significant role in
the proteolytic processing of PrPC.
We then took the more extreme approach of introducing large
deletions into the HC. BOM24 had an eight-amino acid deletion
which mildly reduced the hydrophobicity around the a-cleavage
site (Fig. 3A,C), whereas BOM23 had a larger deletion extending
upstream to the beginning of the HC and strongly reducing its
hydrophobicity (Fig. 3A,C). Measurements of C1 (Fig. 3D–E)
showed that a-cleavage was mildly inhibited in BOM24 and
strongly inhibited in BOM23 (Fig. 3D–E). These results suggest
that a-cleavage may be inhibited in mutants with low hydropho-
bicity in the HC or, alternatively, that inhibition is primarily
dependent on the size of the deletion.
Definition of a Domain Regulating a-Cleavage
Because PrPC proteolysis was not prevented by the point
mutations enumerated above, whereas larger deletions within the
HC impaired a-cleavage, we extended our investigations of PrPC
deletions. We firstly assessed the cleavage efficiency of C40, the
construct with a 30-residue deletion encompassing most CC and
HC (Fig. 4A). Essentially no C1 was observed when the C40
construct was transfected into Hpl cells (Fig. 4B–C), thereby
establishing that the region encompassing residues 100–129 is
essential for modulating a-cleavage of PrPC. To define the
minimal region essential for a-cleavage, the generation of C1
was assessed in PrPC constructs bearing smaller deletions within
the stretch 100–129. BOM12 and BOM13 had a deletion of the
a-cleavage site and of further upstream residues (Fig. 4A),
whereas C39 contained a deletion of the entire palindrome
downstream of the a-cleavage site. Finally, BOM14 had a
deletion downstream of the palindrome but maintained the a-
cleavage site (Fig. 4A).
No differences in a-cleavage were detected between BOM12,
BOM14, and PrPC (Fig. 4B–C). In contrast, BOM13, with
deletion in the residues 105–110, and C39, which lacks the
domain 111–120, showed about 50% reduction in C1 abundance
(Fig. 4B–C). This suggests that the space occupied by residues
105–120, but not necessarily the chemical identity of those
residues (Fig. 2), is important for a-cleavage. Surprisingly,
although the removal of the region 100–110 did not affect a-
cleavage in BOM12, the shorter deletion of 105–110 resulted in
about 50% inhibition of a-cleavage in BOM13. This suggests a
negative modulation of cleavage by residues 100–104 in this
context. The sequence present in BOM13, but absent from
BOM12, is KPSKP (Fig. 4A) and is highly conserved domain in
mammals [32,33]. Even lower vertebrates, including chicken and
fish, generally conserve the KPxKP motif [33,34]. Perhaps the a-
PrPase is partially blocked in BOM13, but not in BOM12, due to
an entity interacting with the conserved region 101–104.
Alternatively, this constellation of prolines and charged residues
may contribute to a decrease in the flexibility of this segment and,
in turn, enhance the antagonistic effects of the deletion on the
efficiency of a-cleavage.
Prion Protein
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Because the domain 105–120 appeared to be important for a-
cleavage, we set out to identify the minimal region within this
domain that would affect the proteolytic processing of PrPC. For
this purpose, we assessed the degree of C1 generation in the
mutants BOM17, BOM15, and BOM16 bearing deletions of 14,
9, and 4 residues within the domain 105–120, respectively
(Fig. 4A). Quantification of PrPC proteolysis in these constructs
revealed a C1 reduction by about 28% for BOM16 (4-residue
deletion; Fig. 4B–C). The extent of cleavage impairment was
proportional to the size of the deletions (Fig. 4B–D), provided that
said deletions encompassed the a-cleavage site and were situated
within the domain 106–119. When the domain 106–119 was
deleted, a-cleavage was only marginally higher than in C40
(Fig. 4B–D). These findings suggest that a-cleavage is not
controlled by a specific primary sequence, but rather by the
length of the unstructured stretch encompassing residues 105–120.
Accordingly, 50% cleavage inhibition is expected to be achieved
with a deletion of six residues (Fig. 4D).
Figure 3. Evaluation of the role of the hydrophobicity in the a-cleavage site region in modulating a-cleavage. A: Amino acid sequence
alignment of the PrPC constructs used. Numbers represent amino-acid residues. The positive residues of the charge cluster, the hydrophobic core,
and the palindrome are highlighted. Arrow: a-cleavage site. Grey: non-mutated residues. Green: deletions or mutations into non-charged residues. B:
Superimposed hydrophobicity plots of the region 90–153 of PrPC (green) and mutants BOM26 (black), BOM27 (blue), and BOM25 (red). C:
Hydrophobicity plot of the region 90–153 of BOM23 in the upper panel and BOM24 in the lower panel. Vertical line represents the site of the deletion
spanning the residues 111–125 and 118–125 for BOM23 and BOM24 respectively. Numbers adjacent to the vertical line indicate the amino acid
residues flanking the deletion of the mutants. D: Western blot of PNGase treated cell lysates of Hpl cells transfected with the various PrPC deletion
constructs used in the current study. Detection was done with POM1. Arrows point to the full length PrP (FL) and C1 fragment. E: Quantification of
the percentage of a-cleavage of the various PrPC mutants, based on densitometry of western blots, from which (D) is representative. Quantifications
were calculated in the linear range of the densitometric signal of independent experiments. Values refer to the amount of C1 generation comparing
to total abundance of PrPC, and are normalized to cleavage of non-mutated PrPC, which was assessed in the same blot. Error bars represent the SEM.
doi:10.1371/journal.pone.0009107.g003
Prion Protein
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Figure 4. Search for a defined domain within PrPC that regulates its a-cleavage. A: Amino acid sequence alignment of the PrPC constructs
used. Numbers represent amino acid residues. The positive residues, the charge cluster, hydrophobic core, palindrome and the conserved 100–104
domain are highlighted. Arrow: a-cleavage site. B: Western blot of PNGase treated cell lysates of Hpl cells transfected with the PrPC deletion
constructs used in the current study. Detection was done with POM1. Arrows point to the full length PrP (FL) and C1 fragment. C: Quantification of
the percentage of a-cleavage of the various PrPC mutants, based on densitometry of western blots, from which (B) is representative. Quantifications
were calculated in the linear range of the densitometric signal of independent experiments. Values refer to the amount of C1 generation comparing
to total abundance of PrPC, and are normalized to cleavage of PrPC, which was assessed in the same blot. Error bars represent the SEM. D: Graphic
illustrating the percentage of a-cleavage impairment of PrPC deletion mutants. Points correspond to the average value illustrated in (C), for the
samples PrPC, BOM16, BOM15, BOM17 and C40, which have 0, 4, 9, 14 and 30 amino acids deleted, respectively. In x-axis are plotted the size of the
deletion of each of these constructs. Dashed line refers to the estimated deletion size that would result in 50% inhibition of a-cleavage.
doi:10.1371/journal.pone.0009107.g004
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a-Cleavage of Neurotoxic PrP Variants
Increased hydrophobicity in the HC may result in increased
generation of a transmembrane species of PrP termed CtmPrP,
which may be toxic [35]. This was mainly supported by a study
where toxicity and prion replication were assessed in a transgenic
mouse model that highly overexpressed the mutant PrPKH109–110II
in the absence of wild-type PrPC [35]. This PrPC mutant had the
two charged amino acids of the a-cleavage site substituted by
hydrophobic isoleucines. It was suggested that enhanced hydro-
phobicity on the PrP molecule led to higher CtmPrP formation and
increased PrPSc accumulation [35]. Here we assessed whether the
toxicity of this mutant might be explained by inhibition of a-
cleavage. For this purpose the proteolysis of PrPKH109–110II was
assessed in Hpl cells. Quantification of a-cleavage suggested that
this may be partially inhibited (Fig. 5A,D), yet the yield of C1 was
very variable and ranged between 11% and 30% inhibition. In
one single sample we observed 86% inhibition.
In order to further test the hypothesis that a slight impairment
on PrPC cleavage could be mildly toxic and therefore be translated
into human diseases, the degree of proteolysis of constructs
carrying mutations linked to human prion diseases was quantified.
PrPP101L is associated with Gerstmann-Stra¨ussler-Scheinker (GSS)
syndrome [36], PrPD177L replicates fatal familial insomnia (FFI)
[37], and PrPE199K is found in familiar CJD cases [38,39]. For
control, the proteolysis of PrPQ218K was assessed, which is a
construct reported to be a dominant negative of PrPSc replication
[40]. Another control was secPrPC, which is secreted and has been
shown to be convertible into PrPSc, but not fatal in mice [41].
Quantification of C1 generation in Hpl cells expressing these
mutants showed reduced a-cleavage in PrPE199K, and even more
so in PrPD177N (Fig. 5B,D). Also, PrPP101L showed a high
variability in terms of a-cleavage rate, with low values of C1
generation observed sporadically (Fig. 5B,D). In contrast, the
PrPSc dominant negative PrPQ218K was cleaved in a similar
fashion as normal PrPC (Fig. 5A,D), suggesting a link between
toxicity of inherited human prion diseases, and inhibition of a-
cleavage of PrP. However, secPrPC did not show any C1
generation in Hpl cell lysates (Fig. 5B,D), in contrast to a previous
report using human SH-SY5Y cells [13]. In order to clarify this
discrepancy, we assessed the cleavage of this mutant in brain of
transgenic mice expressing secPrPC in Prnp2/2 mice [41]. Also
here we were not able to detect any C1 fragment (Fig. 5C). We
conclude that secPrPC does not generate cell-associated C1 in the
systems analyzed here. This finding, in combination with results
reported elsewhere [42], suggests that the GPI anchor is necessary
for the toxicity of uncleavable PrPC mutants.
Discussion
a-cleavage of PrPC occurs in many cell types and tissues at a
well-defined site located in the unstructured portion of the protein
[10], generating a stable carboxy terminal fragment of ca. 15 kDa
[7,14,43] and an N-terminal fragment of ca. 12 kDa [27,28]. The
robust and stereotypic nature of these processing events suggests
the existence of specific proteases which we term PrPases.
However, we were surprised to find that PrPC proteolysis is
remarkably tolerant of variations in the sequence surrounding the
Figure 5. a-cleavage of PrPC mutants with PrPSc-generating point mutations. A–B: Western blots of PNGase treated cell lysates of Hpl cells
transfected with various PrP mutants. All lanes in (A) belong to the same blot. Detection was done with POM1. Arrows point to the full length PrP (FL)
and C1 fragment. C: Western blot of PNGase treated brain homogenates of mice expressing GPI-anchorless secreted PrPC in Prnp2/2 background,
and wild-type PrPC. D: Quantification of the percentage of a-cleavage of the various PrPC mutants, based on densitometry of western blots, from
which (A) and (B) are representative. Quantifications were calculated in the linear range of the densitometric signal of independent experiments.
Values refer to the amount of C1 generation comparing to total abundance of PrPC, and are normalized to cleavage of wild-type PrPC which was
assessed in the same blot. Error bars represent the SEM.
doi:10.1371/journal.pone.0009107.g005
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site of cleavage. A large number of manipulations had little or no
effect in a-cleavage of PrPC; some of these manipulations were
very far-reaching and included removal of the canonical cleavage
site, inversion of all charges, radical manipulations of the
hydrophobicity, and alteration of the palindrome domain.
As the resolution of SDS-PAGE does not allow for detecting
single amino-acid shifts in the cleavage site, it is possible that some
of the PrPC mutants may have experienced subtle shifts in the a-
cleavage site. Even if that were the case, all manipulations
consistently preserved the generation of a C1 cleavage product
whose abundance and electrophoretic motility was similar to bona
fide C1 generated by proteolysis of wild-type PrPC. Conversely,
deletion of residues 106–119 strongly reduced a-cleavage, whereas
shorter deletions within this region had only a moderate effect.
The efficiency of cleavage was inversely proportional to the size of
deletions centered onto the a-cleavage site.
The results described in this study allow drawing several
surprising conclusions on the molecular preconditions for a-
cleavage of PrPC. Firstly, substitution of positively charged residues
at the a-cleavage site has no major effect on the degree of PrPC
proteolysis. This is in agreement with previous studies of N2a cells
transfected with GFP-fused ovine PrPC mutants [21]. Secondly,
replacement of all six positive charges of the CC with negative
charges, including those of the a-cleavage site, resulted only in a
partial inhibition of C1 generation. Thirdly, even total or partial
substitution of the palindromic alanines flanking the a-cleavage
site with glycines had little impact in the normal proteolysis of
PrPC. This observation contradicts a previous report in murine
N2a cells [19], yet was particularly robust in our experience and
appears to be valid in both murine and human cells. Fourthly,
amino acid substitutions reducing the hydrophobicity of the region
surrounding the a-cleavage site failed to reduce the proteolysis of
PrPC. However, impairment of a-cleavage was observed upon
substitution of the charged residues within the cleavage site for two
highly hydrophobic isoleucines. Fifthly, deletions in the vicinity of
the a-cleavage site, as the domains 100–110 and 121–129, had no
impact onto cleavage whereas deletions of the domains 105–110
and 111–120 resulted in about 50% impairment on a-cleavage.
The latter result is in agreement with our previous report that a
PrPC mutant lacking residues 114–121 undergoes inefficient a-
cleavage in transgenic mice [14].
It is somewhat counterintuitive that deletion of residues 100–
110 had no apparent effect whereas the shorter deletion 105–110
partially blocked a-cleavage. This finding points to the importance
of the 100–104 KPSKP residues. This region is highly conserved
in vertebrates [33,34] and has been suggested to be important for
protein binding [44]. One of the domains indentified in the
consensus sequence in vertebrates is PxxP, which is an SH3-
binding motif [34,44,45]. All of the above suggests the existence of
a macromolecule that interacts with the domain 100–104 and may
occlude the a-cleavage site. This putative macromolecule may not
necessarily be a protein. Alternatively, a proline kink at the a-
cleavage site may impair the function of the a-PrPase in cis.
In our experiments, the C1 fragment was suppressed below
detectability only when the entire segment 106–119, or major
portions thereof, was removed. However, shorter deletions within
the domain 106–119 centered in the a-cleavage site region only
partially inhibited proteolysis of PrPC. Assuming that the efficiency
of cleavage is linearly dependent on the length of this segment, a
50% blockage of a-cleavage would be obtained with a six-residue
deletion.
In summary, a-cleavage of PrPC has a strong tolerance towards
sequence degeneration. Such tolerance may underlie evolutionary
pressure, since PrPC mutants that do not undergo a-cleavage are
neurotoxic [14,15,16]. We found the determinants of PrPC
cleavage to be invariant in many biological systems, including
Npl cells derived from Prnp2/2 mice [24], human HeLa cells,
mouse embryonic fibroblasts, and transgenic mice [14]. This
suggests that the relevant a-PrPases are functionally conserved and
present in many tissues. What might underlie the surprising
resilience of a-cleavage to sequence variation? Maybe several
distinct proteases display redundant a-PrPase activity. If that were
the case, alterations of the cleavage site may affect the recognition
by some–but not all–proteases, resulting in unhindered global a-
PrPase activity. Alternatively, PrPC may be processed by a single
a-PrPase with high plasticity of its substrate specificity. Examples
of such proteases are the desintegrin and metalloproteases
(ADAM) 10 and 17 (also known as TACE, or a-secretase of
APP). These proteins have been reported to cleave a broad range
of basic, acidic, or zwitterionic substrates [46] with no common
consensus sequences [46,47,48], and have therefore been also
termed ‘‘sheddases’’. The activity of sheddases is typically tolerant
of point mutations [49,50] and their cleavage sites appears to rely
on the distance of unfolded substrate regions from the cell
membrane [49]. Analogously, the a-cleavage site of PrPC is
localized in an unfolded region and is flanked by a hydrophobic
domain which may associate with the cell membrane [31].
Analogously to various substrates of ADAM 10 and 17, the
cleavage of PrPC appears to tolerate charge removal or inversion.
Indeed, ADAM-10 and ADAM-17 have been suggested to act as
a-PrPases [51,52], yet this assertion is not entirely uncontroversial.
The function of ADAMs necessitates divalent cations, and it was
reported that 10 mM of EDTA does not inhibit a-cleavage [12],
yet others have reported that 5 mM EDTA inhibits cleavage in a
Cu2+ and Fe2+ dependent manner [43].
Some of the mutations analogous to those found in familial
prion diseases appear to impair the proteolytic processing of
PrPC. In addition, a-cleavage appeared to be also impaired in
PrPKH109–110II, which is toxic in transgenic mice [35]. In
construct PrPQ218K, which dominantly inhibits PrPSc replication
[40], the degree of a-cleavage was similar to the one detectable in
PrPC. It remains to be established whether PrPC cleavage
inhibition is a cause or a consequence of the toxicity of these
mutants. In this context it may be interesting to assess the degree
of cleavage of these constructs in transgenic mice before the onset
of the disease.
Through the study of a large panel of transgenic mice
expressing many different PrPC mutants, we found that the
toxicity of PrPC deletion mutants was abolished by removal of the
GPI anchor [42]. This finding argues that toxicity is exerted
through some process that occurs at the membrane, such as
interaction with signal-transducing molecules. In this context it is
interesting to note that infection of transgenic mice expressing
secPrP, which did not produce any C1 fragment in their brains,
results in only weak neurotoxicity [41]. These results may be taken
to suggest that similar neuropathogenic cascades are activated
both in scrapie infection and in expression of non-cleavable PrPC
variants.
Absence of a-cleavage is characteristic shared by PrPSc [7,43]
and toxic PrPC mutants [14,15,16], suggesting that a-cleavage is
important for the function of PrPC and possibly even for the
pathogenesis of prion diseases. Yet the identity and the functional
characteristics of the enzymes relevant for this process are still
unknown. A promising way forward may take advantage of newly
developed antibodies [26] that allow for isolation and native
elution of PrPC-containing supramolecular assemblies [53]. The
differential analysis of multiprotein complexes containing variants
of PrPC that are permissive or refractory to cleavage may lead the
Prion Protein
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identification of the relevant sheddases and possibly also of
downstream players involved in prion toxicity.
Materials and Methods
Cloning
Murine PrPC was amplified from total brain cDNA, using the
primers SY6 and SY7 (Table S1), which introduces the BamHI
and the SalI cleavage sites, respectively. The PCR products were
digested with BamHI and SalI and the targeted vector, pBMN-I-
EGFP (Addgene, plasmid 1736), was digested with BamHI and
XhoI. Fragments were later purified from an agarose gel, using the
Amersham GFX PCR DNA and Gel Band Purification Kit. The
PCR products and the open plasmid were ligated using the Roche
Rapid DNA Ligation Kit. The products were once again purified
using Amersham GFX PCR DNA and Gel Band Purification Kit,
and transformed into TOP10 competent E. coli (Invitrogen). Other
constructs were performed in two PCR steps using the primers and
templates listed in Table S1. In the first step, PCR was performed
with: 1) SY6 (Table S1) and the reverse plasmid referred in Table
S1; 2) SY7 (Table S1) and the forward plasmid referred in Table
S1. The second step was performed with a PCR using 1 uL of
PCR product 1) and 2), and using SY6 and SY7 to make the full
construct. The construct secPrP was cloned by one additional step
with SY6 and A33 primers (Table S1). PCR product purification,
digestion and ligation were done in a similar way as described for
PrPC. Constructs PrPD118–125 and PrPD111–125 were made using
the QuikChange kit (Stratagene), using the primers indicated in
Table S1. Dv1 construct originates from previous experiments
[54].
Analysis of the Constructs
Most of the work was performed in Hpl cells [25]. Other cell
lines used were N2a-Pk1 [22], NIH-3T3 [23], Npl [24], Hela [29].
Primary embryonic fibroblasts obtained from E12,5 Prnp2/2
embryos and brains from mice were also used.
Transfection was performed using Lipofectamine (Invitrogen)
and Plus Reagent (Invitrogen), into 80% confluent cells. Cells were
harvested using 10 mM EDTA, 2 days after transfection. Cell lysis
was performed on ice for 1 h, using 1% Triton-X-100 and 1%
NP-40, in Tris buffer at pH 7.5, with NaCl and protease inhibitors
(Complete; Roche). For brain lysis, a 10% homogenate was
prepared in Ripa buffer with protease inhibitors (Complete;
Roche), and lysed for 1 h on ice. For all samples, lysate
supernatant was collected after centrifugation for 30 min at
16000 g at 4uC. Supernatant was then treated with PNGase
(NEB), and loaded onto 12% SDS-polyacrylamide gels. After
electrophoresis, proteins were transferred to nitrocellulose mem-
branes (Schleicher & Schuell) by wet blotting. Primary antibody
was anti PrPC POM1 [26], POM11 [26], or POM19 [26] in case
of human derived Hela cells, diluted 1:10’000 from a 1 ug/ul
stock. Peroxidase-labelled anti-mouse IgG1 diluted 1:10’000
(Zymed) was used as secondary antibody. Antibodies were probed
for 1 h at room temperature or over-night at 4uC in a 1% Top-
Block solution (FLUKA) in PBS-Tween 20. For membrane
blocking, a 5% Top-Block solution was used. Development was
done using ECL detection system (Pierce). Densitometric assess-
ment of PrP bands was performed using TINA v2.09g (Raytest
Isotopenmessgera¨te), in the linear range of the band intensity.
Hydrophobicity plots were calculated for using DNAMAN
software (Lynnon BioSoft, Canada), for window intervals of nine
residues.
Immunoprecipitation and Western Blot Analysis of N-
Fragment
For each sample, immunoprecipitation was performed in 7 mL
of Optimem media, supplemented with a protease inhibitors
(Complete; Roche), and collected after 8 h culture of 90%
confluent cells in T75 flasks. Dynabeads M-280 tosyl-activated
(Invitrogen) were coated according to manufacture procedures.
Beads were washed twice with 0.5% CHAPS, 0.5% NP-40, and
twice with 1% CHAPS, 1% NP-40. Elution was performed by
boiling the beads for 10 min at 95uC in Loading Buffer 2X
(Invitrogen).
Supporting Information
Table S1 List of the primers used in this study.
Found at: doi:10.1371/journal.pone.0009107.s001 (0.11 MB
DOC)
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